Posted by Michael Wonder on 10 Oct 2024
Pulmonary fibrosis drug Ofev nears key reimbursement decision in Korea
10 October 2024 - The Pharmaceutical Reimbursement Evaluation Committee under HIRA is reportedly set to review Ofev (nintedanib), a treatment for pulmonary fibrosis.
Some industry insiders argue that a flexible application of the Incremental cost effectiveness ratio threshold value is essential for Ofev, unreimbursed for the past eight years, to pass the committee’s economic assessment.
